Research Output Journal of Public Health and Medicine 3(2):1-4, 2024

ROJPHM

ISSN ONLINE: 1115-9715
ISSN PRINT: 1115-6147

https://rojournals.org/roj-public-health-and-medicine/

https://doi.org/10.59298/ROJPHM/2024/3214

The Role of Genomics in Predicting Drug Response

Nyiramana Mukamurera P.

Faculty of Medicine Kampala International University Uganda

ABSTRACT

The integration of genomics into pharmacology has revolutionized the prediction of drug responses, enabling the personalization of medicine. Advances in next-generation sequencing and pharmacogenomics allow for the identification of genetic variants that influence drug efficacy and toxicity. By analyzing genetic data, researchers can develop predictive models that optimize drug selection and dosing based on individual patient genomes. This approach is particularly relevant in cancer treatment, where targeting specific genetic mutations enhances therapeutic outcomes. However, challenges remain in the annotation of non-coding regions and ethical concerns related to personalized medicine. This paper examines the current advancements in genomic technologies, key genetic variants affecting drug response, and their clinical applications, along with the potential future directions in this field.

Keywords: Genomics, Pharmacogenomics, Personalized Medicine, Next-Generation Sequencing, Drug Response Prediction.

INTRODUCTION

The rise of modern genomic techniques, particularly second-generation sequencing, has ushered in an unprecedented depth of knowledge regarding a patient's genomic variants. A significant portion of this information relates to variation within individual genes, collectively described as 'genotype' or 'genetic information.' A long-standing vision in pharmacology is to develop tailored applications of drugs in individual patients based on their genomic information. The objectives of treatment with anticancer drugs, which aim to eradicate or halt disease progression while preserving healthy tissue, closely align with this vision of personalized medicine. The toxic effects of anticancer agents are frequently species- or strain-dependent and can be mitigated through appropriate modifications of their chemical structure or dosing regimen. The construction of pharmacogenomic models from quantitative high-throughput drug response data and genomic information may enable efficient drug development by allowing drug efficacy and toxicity to be assessed before clinical application [1]. Drug response prediction models require screening of drug responses and genomic data in cell lines and tumors. Drug-response profiling can be achieved using colorimetric assays. Selective efficacy for cancer cells can be discovered by targeting cancer opportunity niches. Untested drug predictions rely on drug-target information in public databases. Genomic data can be used to build predictive models for guiding therapy. A combined statistical and bioinformatics approach optimizes model parameters using training datasets. External genomic drug-response models quantify the influence of a cell line or tumor's genome on drug response. Predictions for average drug response can be derived based on genomic features. Global and target models have successfully predicted drug responses in pan-cancer settings [2].

GENETIC VARIABILITY AND PHARMACOGENOMICS

Even though drugs that have the same active ingredient may behave quite differently for different patients, some of the causes of these differences are still currently unknown. Individual differences in

demographic features, lifestyle, and other factors, along with genetic variability, are likely to account for many of these differences in drug efficacy and toxicity. Pharmacogenomics is the study of how variations in the genome impact the actions of drugs. Even though all people have very similar genomes, some variation makes them respond differently to chemicals that are otherwise very similar. Genomes contain polymorphisms of various sizes, ranging from single nucleotide polymorphisms to larger deletions or insertions of genes or segments of chromosomes. The latter can have more dramatic effects on individual response because they can completely remove or duplicate the effects of many genes coding for different proteins, such as drug transporters, drug metabolizing enzymes, and drug targets [3]. Single nucleotide polymorphisms (SNPs) occur when a single nucleotide differs in a small portion of the population. SNPs can have various consequences, such as changing protein structure and altering DNA regions that impact protein activity. Identifying SNPs related to drug metabolism, transport, and target activity is valuable for clinical purposes. Discovering genes encoding drug metabolizing enzymes has been crucial for avoiding dangerous side effects. Next-generation sequencing technologies allow the description of thousands of genes and their polymorphisms, with the hope of improving drug prescription and minimizing adverse effects based on individual genotypes [4].

KEY GENETIC VARIANTS AFFECTING DRUG RESPONSE

Individual differences in drug response can be partially attributed to genetic factors. With the advancement of pharmacogenomics, the influence of genes on drug response has gained interest among scientists and healthcare professionals. A comprehensive understanding of pharmacogenomics may enable more precise and efficient usage of medicines. Genetic variants within genes encoding drug metabolism enzymes, drug transport proteins, receptors, and downstream signaling proteins are associated with individual variability in drug response. This content discusses the major pharmacogenomic variants and their impact on the clinical response to drugs [5]. Genetic changes affect drug response. Enzymes modify drugs and impact efficacy and toxicity. Variants in enzymes influence dose and drug concentration. Variations in drug transport proteins impact bioavailability. Genes coding affinity proteins determine drug efficacy. CYP2C9 metabolizes many drugs. Variants in CYP2C9 can lead to drug accumulation and toxicity. Certain individuals require higher doses of Warfarin due to genetic variants. Carriers of CYP2D6 gene variants are less likely to benefit from codeine. Testing for key variants can prevent adverse drug responses. Understanding drug response genes can personalize medicine for specific populations [6].

GENOMIC TECHNOLOGIES FOR DRUG RESPONSE PREDICTION

The development of safe and effective therapies is a continual challenge in both preclinical and clinical stages of drug development. The rise of genomics and genomic technologies has aided the pharmaceutical industry with new drugs in the preclinical stage that have shown little therapeutic potential after clinical trials. Genomics, the collection of all genes and their different variations, is expected to lead to improvements in the efficacy of candidate drugs entering clinical trials and treatment personalization. Genomic technologies apply to the quickly deteriorating research and development of drugs, specifically focusing on patient selection for late-phase clinical trials. The rationale for patient stratification is that it can increase the anticipated treatment benefit for the selected patient subsets, which widens the therapeutic index of drugs. Biomarkers, which can be detected either directly with genes or gene products or indirectly via other closely related molecular substances, provide information on drug efficacy and toxicity mechanisms and can be used for patient stratification. Biomarkers can be classified as prognostic, predictive, or both. Next-generation sequencing technology, which assembles and sequences millions of short DNA fragments in parallel, has developed genomic biomarkers for response to targeted therapies. NGS technologies have high throughput and sensitivity, enabling the detection of biomarker variants at low frequencies. In a study on cellular models of breast and lung cancer exposure to targeted inhibitors, NGS analysis successfully identified tumor sequencing variants associated with drug response. Genomic technologies can also support the approval of drugs based on novel mechanisms of action, which is currently becoming the trend with potential 'silver' bullets entering the drug development pipeline [7].

NEXT-GENERATION SEQUENCING (NGS)

NGS is widely used for genomics, reducing sequencing time and cost. NGS generates random sequences, which must be pre-processed and assembled. Commercial NGS systems offer genomic/transcriptomic sequences. Platforms are classified as SMRT sequencing, nanopore sequencing, and SBS. SMRT sequencing uses DNA polymerase to detect labeled nucleotides. Nanopore sequencing detects ion current changes when DNA passes through a nanopore. SBS detects labeled nucleotides during base-by-base sequencing. Each chemistry has unique traits and advantages/disadvantages [8]. Commercial platforms

range from small-scale benchtop devices to large throughput systems for sequencing projects. Before NGS, sequencing was time-consuming and expensive. Now, NGS allows for the analysis of whole genomes, generating large amounts of genomic data. NGS also has a significant impact on transcriptomics, reducing costs and improving resolution for phylogeny. Comparative analysis of eukaryote genomes is now possible for plant genomes [9].

CLINICAL APPLICATIONS OF GENOMIC DATA IN PERSONALIZED MEDICINE

One of the earliest examples of whole-exome sequencing in clinical practice was the case of a young girl suffering from a devastating neurological condition. The diagnostic odyssey took four years and led to multiple inconclusive tests. Whole-exome sequencing was performed at a clinical service and compared to the maternal and paternal samples. A de novo mutation was detected in the gene SCN2A, which had previously been associated with the recessive form of the condition. The family subsequently received genetic counseling and had the option of prenatal testing in subsequent pregnancies. This case clearly demonstrates how genomic technologies can have a direct impact on the improvement of diagnosis and subsequent clinical management. One interesting aspect of this case was the use of a bioinformatics pipeline, which enabled the simultaneous identification of single nucleotide variants, insertions, deletions, copy number variants, and other variant types. Several other similar cases have since been published [10]. Kidney cancer is a top cause of global cancer deaths. Its genetic basis is diverse, affecting responses to treatment. Sequencing tumors and normal samples identified mutations, variations, and fusions. Functional validation is essential for improving therapy. Mutations were analyzed to understand biological pathways. Breast cancer is the most common worldwide. A gene classifier was developed to identify high-risk patients. Validation datasets were used and correlation coefficients were high. Luminal A and HER2-enriched cancers had poor outcomes. Precision medicine should account for ethnic disparities [11].

CASE STUDIES IN PRECISION MEDICINE

Genomic analysis is crucial for personalized drug response prediction. One example is using pharmacogenomic testing to predict clopidogrel effectiveness in cardiovascular patients. CYP2C19 gene variations can alter drug metabolism and increase cardiovascular risks. Commercial labs developed tests based on CYP2C19 variants, which were proven beneficial in a multicenter trial with 18,000 patients. These findings led to the integration of this testing into clinical guidelines [12]. A case study examines the implementation of PDP for patients with Mycobacterium tuberculosis. Inadequate treatment leads to higher care costs. Current regimens can be improved using whole genome sequencing. A clinical study on drug-resistant strains of Mtb was conducted, developing a model for predicting drug resistance. This model improves personalized treatment and commercial software was created for public use. The success of this PDP illustrates the implications of genomic analysis in precision medicine [13].

CHALLENGES AND FUTURE DIRECTIONS IN GENOMIC PREDICTION OF DRUG RESPONSE

The genomic prediction of drug response holds great promise for precision medicine, but several challenges remain. These challenges encompass various aspects, including biological, technical, and ethical considerations, as well as potential future directions for addressing them. Enhancing the annotation of non-coding regions of the genome is one area for improving tissue and drug coverage and exploring the potential of large-scale expression quantitative trait loci studies. Other possible approaches include the use of multi-omics data and advanced machine learning techniques such as deep learning to unravel complex nonlinear perturbation-response relationships. Alternatively, integrating causative markers can leverage existing genomic variations. Furthermore, there is a need for the development of standards for omic technologies and gene-panel/multi-omics-based drugs, as well as accurately assessing the risks and benefits of personalized medicine [2]. Candidate genes from genome-wide association studies (GWAS) are often found in non-coding regions of the genome. Enhancing annotation for non-coding variants associated with drug response is a priority. GWAS hits with unknown mechanisms and GWAS hits tagged by protein-coding markers are being prioritized. Large-scale studies with post-mortem human brain tissues are underway, focusing on common SNPs and drugs with polygenicity evidence. Efforts are being made to explore the potential of computed cell-sensitive markers. Future directions include the development of smart and sensitive drugs and laboratory-developed tests. Concerns about the quality and validity of data from laboratory-developed tests exist due to a lack of regulation. Publishing operational proof-of-concept studies of drug-gene pairs for small-scale pre-dosing genomic

arm-sequence strategies is encouraged. The need for uniform standards for mic technologies and multi-omic analyses are recognized [14].

CONCLUSION

The role of genomics in predicting drug responses is transforming the field of personalized medicine by offering more precise, effective, and safer therapeutic options. Genomic technologies such as next-generation sequencing allow for the identification of biomarkers and genetic variants that influence drug metabolism, transport, and efficacy. These advancements are paving the way for personalized drug regimens, particularly in oncology, where treatment strategies can be tailored to an individual's genetic profile. However, challenges such as the need for better annotation of non-coding regions and addressing ethical concerns must be addressed to fully realize the potential of pharmacogenomics in clinical practice. Continued research and the integration of multi-omics data and machine learning hold promise for overcoming these hurdles and further advancing the field.

REFERENCES

1. Qin W, Lu X, Shu Q, Duan H, Li H. Building an information system to facilitate pharmacogenomics clinical translation with clinical decision support. Pharmacogenomics. 2022 Jan 1;23(1):35-48.
2. Adam G, Rampášek L, Safikhani Z, Smirnov P, Haibe-Kains B, Goldenberg A. Machine learning approaches to drug response prediction: challenges and recent progress. NPJ precision oncology. 2020 Jun 15;4(1):19. nature.com
3. Singh DB. The impact of pharmacogenomics in personalized medicine. Current Applications of Pharmaceutical Biotechnology. 2020:369-94.
4. Schlosser P, Li Y, Sekula P, Raffler J, Grundner-Culemann F, Pietzner M, Cheng Y, Wuttke M, Steinbrenner I, Schultheiss UT, Kotsis F. Genetic studies of urinary metabolites illuminate mechanisms of detoxification and excretion in humans. Nature genetics. 2020 Feb;52(2):167-76. nih.gov
5. Bergström A, McCarthy SA, Hui R, Almarri MA, Ayub Q, Danecek P, Chen Y, Felkel S, Hallast P, Kamm J, Blanché H. Insights into human genetic variation and population history from 929 diverse genomes. Science. 2020 Mar 20;367(6484):eaay5012. nih.gov
6. Zhao M, Ma J, Li M, Zhang Y, Jiang B, Zhao X, Huai C, Shen L, Zhang N, He L, Qin S. Cytochrome P450 enzymes and drug metabolism in humans. International journal of molecular sciences. 2021 Nov 26;22(23):12808. mdpi.com
7. Kiriiri GK, Njogu PM, Mwangi AN. Exploring different approaches to improve the success of drug discovery and development projects: a review. Future Journal of Pharmaceutical Sciences. 2020 Dec;6:1-2. springer.com
8. Satam H, Joshi K, Mangrolia U, Waghoo S, Zaidi G, Rawool S, Thakare RP, Banday S, Mishra AK, Das G, Malonia SK. Next-generation sequencing technology: current trends and advancements. Biology. 2023 Jul 13;12(7):997. mdpi.com
9. Ejigu GF, Jung J. Review on the computational genome annotation of sequences obtained by next-generation sequencing. Biology. 2020 Sep 18;9(9):295.
10. Aaltio J, Hyttinen V, Kortelainen M, Frederix GW, Lönnqvist T, Suomalainen A, Isohanni P. Cost-effectiveness of whole-exome sequencing in progressive neurological disorders of children. European Journal of Paediatric Neurology. 2022 Jan 1;36:30-6.
11. Genovese A, Butler MG. Clinical assessment, genetics, and treatment approaches in autism spectrum disorder (ASD). International journal of molecular sciences. 2020 Jul 2;21(13):4726.
12. Quazi S. Artificial intelligence and machine learning in precision and genomic medicine. Medical Oncology. 2022 Jun 15;39(8):120.
13. Zhong Y, Xu F, Wu J, Schubert J, Li MM. Application of next generation sequencing in laboratory medicine. Annals of laboratory medicine. 2021 Jan 1;41(1):25-43. koreamed.org
14. Schipper M, Posthuma D. Demystifying non-coding GWAS variants: an overview of computational tools and methods. Human molecular genetics. 2022 Oct 15;31(R1):R73-83.

CITATION: Nyiramana Mukamurera P. (2024).The Role of Genomics in Predicting Drug Response. Research Output Journal of Public Health and Medicine 3(2):1-4. https://doi.org/10.59298/ROJPHM/2024/3214